Suchergebnisse - (Subject:"Siltuximab")

PubPharm (121)

101

Complete remission achieved with single agent CNTO 328, an anti-IL-6 monoclonal antibody, in relapsed and refractory myeloma

enthalten in: Clinical lymphoma, myeloma & leukemia | 2013

von Chari, A. | Pri-Chen, H. | Jagannath, S.

102

A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

enthalten in: British journal of haematology | 2013

von Voorhees, P. | Manges, R. | Sonneveld, P. | +15

103

A novel approach for the simultaneous quantification of a therapeutic monoclonal antibody in serum produced from two distinct host cell lines

enthalten in: mAbs | 2013

von Geist, B. | Davis, D. | McIntosh, T. | +5

104

Paraneoplastic thrombocytosis in ovarian cancer

enthalten in: The New England journal of medicine | 2012

von Stone, R. | Nick, A. | McNeish, I. | +31

ErratumIn: N Engl J Med. 2012 Nov;367(18):1768 Lamkin, Donald [added]

105

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer

enthalten in: European journal of cancer (Oxford, England : 1990) | 2012

von Fizazi, K. | De Bono, J. | Flechon, A. | +8

106

The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study

enthalten in: The Prostate | 2011

von Karkera, J. | Steiner, H. | Li, W. | +10

107

Interleukin-6 as a therapeutic target in human ovarian cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2011

von Coward, J. | Kulbe, H. | Chakravarty, P. | +16

CommentIn: Clin Cancer Res. 2011 Dec 15;17(24):7837; author reply 7838. - PMID 22147939

108

Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study

enthalten in: British journal of clinical pharmacology | 2011

von Xu, Z. | Bouman-Thio, E. | Comisar, C. | +5

109

JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling

enthalten in: Molecular cancer therapeutics | 2011

von Song, L. | Rawal, B. | Nemeth, J. | +1

110

Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma

enthalten in: British journal of haematology | 2011

von Hunsucker, S. | Magarotto, V. | Kuhn, D. | +10

[1]
« Vorheriger
3
4
5
6
7
8
9
10
11
12
13
Nächster »
[13]